Knee osteoarthritis (OA) imposes a substantial economic burden on the U.S. healthcare system, costing billions of dollars annually. The condition often begins with localized cartilage defects that, if left untreated, can progress to advanced joint degeneration requiring costly interventions. Regentis Biomaterials Ltd. (NYSE American: RGNT) is addressing this challenge with Gelrin C, a cell-free, off-the-shelf hydrogel designed to fit seamlessly into existing surgical workflows. Unlike complex cell-based therapies that require multiple procedures and specialized laboratory processing, Gelrin C offers a 10-minute, single-step procedure, making it a practical option for surgeons and patients alike.
Approximately 470,000 cartilage repair procedures are performed each year in the U.S., representing a multi-billion-dollar market. As healthcare providers, payers, and patients seek more efficient regenerative solutions, Gelrin C targets the critical window before cartilage damage progresses to full-blown OA. Articular cartilage has limited self-repair capacity, so early intervention is key to preventing deterioration. By providing a synthetic scaffold that supports tissue regeneration, Gelrin C aims to reduce the long-term costs associated with joint replacement and other advanced OA treatments.
The significance of this innovation lies in its potential to shift the treatment paradigm from reactive to proactive. With the aging population and rising rates of obesity and sports injuries, the demand for effective cartilage repair options is growing. Regentis' approach could help close the $15 billion spending gap by offering a cost-effective solution that improves patient outcomes and reduces the economic burden of OA. For more information on this development, visit the company's newsroom at ibn.fm/RGNT.
This content was disseminated as part of a paid marketing engagement with IBN. Regentis Biomaterials Ltd. (NASDAQ: RGNT) pays IBN $30,000 per quarter for a total of 180 days for coverage. Full terms and disclaimers are available on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
